Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a less extensive lung cancer surgery be just as effective?

NCT ID NCT07801430

Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 09, 2026 · Updated 2 times

Summary

This trial studies people with early-stage non-small cell lung cancer who are having surgery to remove the tumor. During surgery, doctors usually also remove lymph nodes from a specific area called station 4L. The trial randomly assigns half of the participants to have those lymph nodes removed and the other half to skip that step. The goal is to see if skipping the removal is just as good at preventing the cancer from coming back within three years, while possibly reducing side effects from surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Station 4L lymph node dissection, a surgical procedure to remove lymph nodes in a specific area of the chest during lung cancer surgery
What this could lead to
If skipping this lymph node removal is as good as doing it, patients might have fewer surgery-related side effects while keeping the same chance of staying cancer-free.
What could go wrong
This is a randomized trial, but the outcome depends on long-term follow-up. There is a risk that skipping the dissection could allow cancer to spread undetected, and the results may not apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 384 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 75 years. * A single solid pulmonary nodule (consolidation-to-tumor ratio of 1.0) located in the left lung. * Resectable clinical stage I (T1-T2aN0M0) non-small cell lung cancer, with a maximum tumor diameter of 4 cm or less, evaluated by positron emission tomography/computed tomography. * Planned complete lung resection by segmentectomy or lobectomy with systematic mediastinal lymph node dissection. * Intraoperative frozen-section pathological confirmation of invasive non-small cell lung cancer before randomization. * Able to provide written informed consent and willing to complete the protocol-specified follow-up. Exclusion Criteria: * Intraoperative or postoperative pathology indicates noninvasive non-small cell lung cancer. * Surgical procedure other than segmentectomy or lobectomy. * Incomplete tumor resection or residual tumor. * History of another malignant tumor. * History of previous lung surgery. * Previous radiotherapy or chemotherapy for the current lung cancer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non small cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Xuhui, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.